Bristol-myers Squibb Compnay

Robert A Mate

John E Macor

Richard Eric Olson

Ivar M McDonald

Joanne J Bronson

Michael Frederick Parker

Dalton King

Lawrence R Marcin

Carl P Bergstrom

F Christopher Zusi

James H Cook, Ii

Christiana I Iwuagwu

Yonghua Gai

Nenghui Wang

Haiquan Fang

Matthew D Hill

Katharine E McElhone

Rex Denton

Ivar M Mcdonald

Kimberley A Lentz

Katharin E McElhone

James H Cook Ii

James H Ii Cook

Christopher F Zusi

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Tricyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

There is provided a series of novel &#x3b1;-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R, Rand Rare defined herein, which are inhibitors of &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.

&#x3b1;-(N-sulfonamido)acetamide derivatives as &#x3b2;-amyloid inhibitors

Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Growing community of inventors

Waterbury, CT, United States of America

Robert A Mate